The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Vir Combination
Influenzinum (2021-2022), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode · INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; HUMAN HERPESVIRUS 1 15 [hp_X]/mL; HUMAN HERPESVIRUS 2 15 [hp_X]/mL; HUMAN HERPESVIRUS 6 15 [hp_X]/mL; HUMAN HERPESVIRUS 5 18 [hp_X]/mL; HEPATITIS B VIRUS 33 [hp_X]/mL; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN 12 [hp_C]/mL; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN 12 [hp_C]/mL; HUMAN HERPESVIRUS 4 16 [hp_C]/mL · Liquid · Oral · Deseret Biologicals, Inc.
NDC 43742-2040-01 · 30 mL in 1 BOTTLE, DROPPER · UNAPPROVED HOMEOPATHIC · View full market →
Medicare Part D
Medicare Part D does not cover homeopathic products, which are not FDA-approved drugs.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Influenzinum (2021-2022), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode (Liquid)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Deseret Biologicals, Inc. | INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; HUMAN HERPESVIRUS 1 15 [hp_X]/mL; HUMAN HERPESVIRUS 2 15 [hp_X]/mL; HUMAN HERPESVIRUS 6 15 [hp_X]/mL; HUMAN HERPESVIRUS 5 18 [hp_X]/mL; HEPATITIS B VIRUS 33 [hp_X]/mL; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN 12 [hp_C]/mL; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN 12 [hp_C]/mL; HUMAN HERPESVIRUS 4 16 [hp_C]/mL | Aug 26, 2026 | Sep 2, 2026 |
| Deseret Biologicals, Inc. | INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 33 [hp_X]/mL; INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_C]/mL; INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_C]/mL; INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED) 15 [hp_X]/mL; HUMAN HERPESVIRUS 1 15 [hp_X]/mL; HUMAN HERPESVIRUS 2 16 [hp_C]/mL; HUMAN HERPESVIRUS 6 18 [hp_X]/mL; HUMAN HERPESVIRUS 5 15 [hp_X]/mL; HEPATITIS B VIRUS 12 [hp_X]/mL; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN 12 [hp_X]/mL; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN 12 [hp_X]/mL; HUMAN HERPESVIRUS 4 12 [hp_X]/mL | Jul 22, 2026 | Aug 19, 2026 |
| Deseret Biologicals, Inc. | HEPATITIS B VIRUS 33 [hp_X]/mL; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN 12 [hp_C]/mL; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN 12 [hp_C]/mL; HUMAN HERPESVIRUS 1 15 [hp_X]/mL; HUMAN HERPESVIRUS 2 15 [hp_X]/mL; HUMAN HERPESVIRUS 4 16 [hp_C]/mL; HUMAN HERPESVIRUS 5 18 [hp_X]/mL; HUMAN HERPESVIRUS 6 15 [hp_X]/mL; INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL; INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) 12 [hp_X]/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Vir Combination — NDC 43742-2040-01," retrieved September 3, 2026, https://drugdashboards.com/drug/43742204001.
Free to cite with attribution — see how the data is put together.